Association Between Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study

Jennifer S Yokoyama, Mina Matsuda-Abedini, Michelle R Denburg, Juhi Kumar, Bradley A Warady, Susan L Furth, Stephen R Hooper, Anthony A Portale, Farzana Perwad, Jennifer S Yokoyama, Mina Matsuda-Abedini, Michelle R Denburg, Juhi Kumar, Bradley A Warady, Susan L Furth, Stephen R Hooper, Anthony A Portale, Farzana Perwad

Abstract

Rationale & objective: Chronic kidney disease (CKD) in children is associated with cognitive dysfunction that affects school performance and quality of life. The relationship between CKD-mineral and bone disorder and cognitive function in children is unknown.

Study design: Observational study.

Participants: 702 children enrolled in the Chronic Kidney Disease in Children (CKiD) Study.

Predictors: Plasma fibroblast growth factor 23 (FGF-23), parathyroid hormone (PTH), calcium, phosphorus, 25 hydroxyvitamin D (25[OH]D), and 1,25 dihydroxyvitamin D (1,25[OH]2D).

Outcomes: Neurocognitive tests of intelligence, academic achievement, and executive functions.

Analytical approach: Linear regression models to analyze the cross-sectional associations between log2FGF-23, 25(OH)D, 1,25(OH)2D, PTH, calcium, and phosphorus z scores and the cognitive test scores of interest after adjustment for demographics, blood pressure, proteinuria, and kidney function.

Results: At baseline, median age was 12 (95% CI, 8.3, 15.2) years and estimated glomerular filtration rate was 54 (40.5, 67.8) mL/min/1.73 m2. In fully adjusted analyses, 25(OH)D, 1,25(OH)2D, PTH, calcium, and phosphorus z scores did not associate with cognitive test scores. In fully adjusted analyses, log2FGF-23 was associated with abnormal test scores for attention regulation (P < 0.05); specifically, Conners' Continuous Performance Test II Errors of Omission (β = 2.3 [1.0, 3.6]), Variability (β=1.4 [0.4, -2.4]), and Hit Reaction Time (β = 1.3 [0.2, 2.4]). Children in the highest FGF-23 tertile group had 7% and 9% greater cognitive risk for Hit Reaction Time and Errors of Omission compared with those in the lowest tertile, respectively. In fully adjusted analyses, higher FGF-23 tertile was associated with increased cognitive risk (P < 0.05) for Errors of Omission (β = 0.4 [0.1, 0.7]) and Hit Reaction Time (β = 0.4 [0.1, 0.7]).

Limitations: The study does not assess the cumulative effects of FGF-23 excess on cognitive function over time. Within-population stratified analyses were not performed due to limited sample size.

Conclusions: In children with CKD, higher plasma FGF-23 level is associated with lower performance in targeted tests of executive function, specifically attention regulation, independent of glomerular filtration rate.

Keywords: FGF-23; chronic kidney disease; cognition; pediatric.

© 2020 The Authors.

Figures

Graphical abstract
Graphical abstract

References

    1. McDonald S.P., Craig J.C. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350:2654–2662.
    1. Saran R., Li Y., Robinson B. US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States. J Am Soc Nephrol. 2015;66 Svii, S1-Svii, 305.
    1. Furth S.L., Hwang W., Yang C., Neu A.M., Fivush B.A., Powe N.R. Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol. 2002;17:450–455.
    1. Gipson D.S., Hooper S.R., Duquette P.J. Memory and executive functions in pediatric chronic kidney disease. Child Neuropsychol. 2006;12:391–405.
    1. Gerson A.C., Butler R., Moxey-Mims M. Neurocognitive outcomes in children with chronic kidney disease: current findings and contemporary endeavors. Ment Retard Dev Disabil Res Rev. 2006;12:208–215.
    1. Harshman L.A., Johnson R.J., Matheson M.B. Academic achievement in children with chronic kidney disease: a report from the CKiD cohort. Pediatr Nephrol. 2019;34:689–696.
    1. Hooper S.R., Gerson A.C., Butler R.W. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:1824–1830.
    1. Bartosh S.M., Leverson G., Robillard D., Sollinger H.W. Long-term outcomes in pediatric renal transplant recipients who survive into adulthood. Transplantation. 2003;76:1195–1200.
    1. Groothoff J.W., Grootenhuis M., Dommerholt A., Gruppen M.P., Offringa M., Heymans H.S. Impaired cognition and schooling in adults with end stage renal disease since childhood. Arch Dis Child. 2002;87:380–385.
    1. Kalirao P., Pederson S., Foley R.N. Cognitive impairment in peritoneal dialysis patients. J Am Soc Nephrol. 2011;57:612–620.
    1. Shimada T., Mizutani S., Muto T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500–6505.
    1. Shimada T., Hasegawa H., Yamazaki Y. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435.
    1. Perwad F., Zhang M.Y., Tenenhouse H.S., Portale A.A. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007;293:F1577–F1583.
    1. Isakova T., Wahl P., Vargas G.S. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370–1378.
    1. Portale A.A., Wolf M., Juppner H. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014;9:344–353.
    1. Fliser D., Kollerits B., Neyer U. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600–2608.
    1. Scialla J.J., Astor B.C., Isakova T., Xie H., Appel L.J., Wolf M. Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol. 2013;24:125–135.
    1. Portale A.A., Wolf M.S., Messinger S. Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol. 2016;11:1989–1998.
    1. Mitsnefes M.M., Betoko A., Schneider M.F. FGF23 and left ventricular hypertrophy in children with chronic kidney disease. Clin J Am Soc Nephrol. 2018;13:45–52.
    1. Faul C., Amaral A.P., Oskouei B. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–4408.
    1. Isakova T., Xie H., Yang W. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432–2439.
    1. Gutierrez O.M., Mannstadt M., Isakova T. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–592.
    1. Parker B.D., Schurgers L.J., Brandenburg V.M. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152:640–648.
    1. Scialla J.J., Xie H., Rahman M. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25:349–360.
    1. Hensel N., Schon A., Konen T. Fibroblast growth factor 23 signaling in hippocampal cells: impact on neuronal morphology and synaptic density. J Neurochem. 2016;137:756–769.
    1. Panwar B., Judd S.E., Howard V.J., Jenny N.S., Wadley V.G., Gutierrez O.M. Vitamin D, fibroblast growth factor 23 and incident cognitive impairment: findings from the REGARDS Study. PLoS One. 2016;11
    1. Drew D.A., Tighiouart H., Scott T.M. FGF-23 and cognitive performance in hemodialysis patients. Hemodial Int. 2014;18:78–86.
    1. Jovanovich A.J., Chonchol M., Brady C.B. 25-Vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population. Clin Nephrol. 2014;82:S1–S4.
    1. Kunert S.K., Hartmann H., Haffner D., Leifheit-Nestler M. Klotho and fibroblast growth factor 23 in cerebrospinal fluid in children. J Bone Miner Metab. 2017;35:215–226.
    1. Furth S.L., Cole S.R., Moxey-Mims M. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol. 2006;1:1006–1015.
    1. Lande M.B., Mendley S.R., Matheson M.B. Association of blood pressure variability and neurocognition in children with chronic kidney disease. Pediatr Nephrol. 2016;31:2137–2144.
    1. Warady B.A., Abraham A.G., Schwartz G.J. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort. Am J Kidney Dis. 2015;65:878–888.
    1. Lande M.B., Gerson A.C., Hooper S.R. Casual blood pressure and neurocognitive function in children with chronic kidney disease: a report of the children with chronic kidney disease cohort study. Clin J Am Soc Nephrol. 2011;6:1831–1837.
    1. Schwartz G.J., Schneider M.F., Maier P.S. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int. 2012;82:445–453.
    1. Ng D.K., Schwartz G.J., Warady B.A., Furth S.L., Munoz A. Relationships of measured iohexol GFR and estimated GFR with CKD-related biomarkers in children and adolescents. Am J Kidney Dis. 2017;70:397–405.
    1. Lockitch G., Halstead A.C., Wadsworth L., Quigley G., Reston L., Jacobson B. Age- and sex-specific pediatric reference intervals and correlations for zinc, copper, selenium, iron, vitamins A and E, and related proteins. Clin Chem. 1988;34:1625–1628.
    1. Ruebner R.L., Laney N., Kim J.Y. Neurocognitive dysfunction in children, adolescents, and young adults with CKD. J Am Soc Nephrol. 2016;67:567–575.
    1. Lande M.B., Kupferman J.C. Blood pressure and cognitive function in children and adolescents. Hypertension. 2019;73:532–540.
    1. Adams H.R., Szilagyi P.G., Gebhardt L., Lande M.B. Learning and attention problems among children with pediatric primary hypertension. Pediatrics. 2010;126:e1425–e1429.
    1. Chen K., Didsbury M., van Z.A. Neurocognitive and educational outcomes in children and adolescents with CKD: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2018;13:387–397.
    1. Yamashita T., Yoshioka M., Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277:494–498.
    1. Hoogman M., Bralten J., Hibar D.P. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry. 2017;4:310–319.
    1. Urakawa I., Yamazaki Y., Shimada T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–774.
    1. Dubal D.B., Yokoyama J.S., Zhu L. Life extension factor klotho enhances cognition. Cell Rep. 2014;7:1065–1076.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel